Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Carcinoma

• Sponsor: Fuda Cancer Hospital, Guangzhou (Other)
• Overall Status: No longer available
• CT.gov ID: NCT02449135
• Collaborator: (none)
• Location: 1

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of nano drug interventional therapy using digital subtraction angiography（DSA） for pancreatic cancer. The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection.

Condition or Disease	Intervention/Treatment	Phase
Pancreatic Cancer	Procedure: interventional therapy

Detailed Description

By enrolling patients with pancreatic cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of nano drug interventional therapy using digital subtraction angiography（DSA）for pancreatic cancer.

Study Design

• Study Type: Expanded Access
• Official Title: Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Carcinoma：Clinical Trial

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 80 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Age:18-80

2. Karnofsky performance status >60

3. Diagnosis of pancreatic cancer based on histology or the current accepted radiological measures.

4. Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ

5. Will receive interventional therapy

6. Life expectancy: Greater than 3 months

7. Patients' routine blood test, liver function and kidney function have no obvious abnormalities

8. Ability to understand the study protocol and a willingness to sign a written informed consent document

Exclusion Criteria:

1. Patients with other primary tumor except pancreatic cancer

2. History of coagulation disorders or anemia

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Central laboratory in Fuda cancer hospital	Guangzhou	Guangdong	China	510000

Sponsors and Collaborators

• Fuda Cancer Hospital, Guangzhou

Investigators

• Study Chair: Lizhi Niu, PhD, Fuda Cancer Hospital

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

• Related Info

Publications

• Niu L, Chen J, Yao F, Zhou L, Zhang C, Wen W, Bi X, Hu Y, Piao X, Jiang F, Zeng J, Liu W, Li J, He L, Mu F, Zuo J, Xu K. Percutaneous cryoablation for stage IV lung cancer: a retrospective analysis. Cryobiology. 2013 Oct;67(2):151-5. doi: 10.1016/j.cryobiol.2013.06.005. Epub 2013 Jun 24.

• Responsible Party: Fuda Cancer Hospital, Guangzhou
• ClinicalTrials.gov Identifier: NCT02449135
• Other Study ID Numbers: Nano drug pancreatic cancer
• First Posted: May 20, 2015
• Last Update Posted: Sep 9, 2021
• Last Verified: Sep 1, 2019

• Keywords provided by Fuda Cancer Hospital, Guangzhou: Pancreatic Cancer; Nano drug
• Additional relevant MeSH terms: Pancreatic Neoplasms

Study Results

No Results Posted as of Sep 9, 2021